Novel biomarkers assist in detection of liver fibrosis in HCV patients

Abstract Background Accurate staging in individuals infected with hepatitis C is imperative to understand their long-term risk for liver-related complications. Liver biopsy has a traditional role to determine the levels of liver fibrosis specifically in hepatitis C virus patients. However, the devel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tamer A. Addissouky, Yuliang Wang, Fayed Attia Koutb Megahed, Ayman E. El Agroudy, Ibrahim El Tantawy El Sayed, Abdel Moneim A. K. El-Torgoman
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	Noninvasive markers Viral hepatitis Chronic liver diseases Biopsy Fibrosis scoring systems Surgery RD1-811 Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/d43205344ee94c458f1abe5fbd6d8336
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d43205344ee94c458f1abe5fbd6d8336
record_format	dspace
spelling	oai:doaj.org-article:d43205344ee94c458f1abe5fbd6d83362021-11-28T12:21:58ZNovel biomarkers assist in detection of liver fibrosis in HCV patients10.1186/s43066-021-00156-x2090-6226https://doaj.org/article/d43205344ee94c458f1abe5fbd6d83362021-11-01T00:00:00Zhttps://doi.org/10.1186/s43066-021-00156-xhttps://doaj.org/toc/2090-6226Abstract Background Accurate staging in individuals infected with hepatitis C is imperative to understand their long-term risk for liver-related complications. Liver biopsy has a traditional role to determine the levels of liver fibrosis specifically in hepatitis C virus patients. However, the development of non-invasive options has reduced the utilization of biopsy in this population. Main body of the abstract Detecting fibrosis levels through blood samples is already an acceptable alternative to biopsy; however, the optimal non-invasive panel has yet to be defined. Our study indicated hyaluronic acid, collagen oligomeric matrix protein, collagen type IV, and liver fibrosis scoring systems to distinguish fibrosis patients from the non-fibrosis group. Short conclusion The combination of these novel biomarkers, H. A, CO-IV, and Comp tests, could be used to accurately stage individuals with hepatitis C.Tamer A. AddissoukyYuliang WangFayed Attia Koutb MegahedAyman E. El AgroudyIbrahim El Tantawy El SayedAbdel Moneim A. K. El-TorgomanSpringerOpenarticleNoninvasive markersViral hepatitisChronic liver diseasesBiopsyFibrosis scoring systemsSurgeryRD1-811Diseases of the digestive system. GastroenterologyRC799-869ENEgyptian Liver Journal, Vol 11, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Noninvasive markers Viral hepatitis Chronic liver diseases Biopsy Fibrosis scoring systems Surgery RD1-811 Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Noninvasive markers Viral hepatitis Chronic liver diseases Biopsy Fibrosis scoring systems Surgery RD1-811 Diseases of the digestive system. Gastroenterology RC799-869 Tamer A. Addissouky Yuliang Wang Fayed Attia Koutb Megahed Ayman E. El Agroudy Ibrahim El Tantawy El Sayed Abdel Moneim A. K. El-Torgoman Novel biomarkers assist in detection of liver fibrosis in HCV patients
description	Abstract Background Accurate staging in individuals infected with hepatitis C is imperative to understand their long-term risk for liver-related complications. Liver biopsy has a traditional role to determine the levels of liver fibrosis specifically in hepatitis C virus patients. However, the development of non-invasive options has reduced the utilization of biopsy in this population. Main body of the abstract Detecting fibrosis levels through blood samples is already an acceptable alternative to biopsy; however, the optimal non-invasive panel has yet to be defined. Our study indicated hyaluronic acid, collagen oligomeric matrix protein, collagen type IV, and liver fibrosis scoring systems to distinguish fibrosis patients from the non-fibrosis group. Short conclusion The combination of these novel biomarkers, H. A, CO-IV, and Comp tests, could be used to accurately stage individuals with hepatitis C.
format	article
author	Tamer A. Addissouky Yuliang Wang Fayed Attia Koutb Megahed Ayman E. El Agroudy Ibrahim El Tantawy El Sayed Abdel Moneim A. K. El-Torgoman
author_facet	Tamer A. Addissouky Yuliang Wang Fayed Attia Koutb Megahed Ayman E. El Agroudy Ibrahim El Tantawy El Sayed Abdel Moneim A. K. El-Torgoman
author_sort	Tamer A. Addissouky
title	Novel biomarkers assist in detection of liver fibrosis in HCV patients
title_short	Novel biomarkers assist in detection of liver fibrosis in HCV patients
title_full	Novel biomarkers assist in detection of liver fibrosis in HCV patients
title_fullStr	Novel biomarkers assist in detection of liver fibrosis in HCV patients
title_full_unstemmed	Novel biomarkers assist in detection of liver fibrosis in HCV patients
title_sort	novel biomarkers assist in detection of liver fibrosis in hcv patients
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/d43205344ee94c458f1abe5fbd6d8336
work_keys_str_mv	AT tameraaddissouky novelbiomarkersassistindetectionofliverfibrosisinhcvpatients AT yuliangwang novelbiomarkersassistindetectionofliverfibrosisinhcvpatients AT fayedattiakoutbmegahed novelbiomarkersassistindetectionofliverfibrosisinhcvpatients AT aymaneelagroudy novelbiomarkersassistindetectionofliverfibrosisinhcvpatients AT ibrahimeltantawyelsayed novelbiomarkersassistindetectionofliverfibrosisinhcvpatients AT abdelmoneimakeltorgoman novelbiomarkersassistindetectionofliverfibrosisinhcvpatients
_version_	1718408046726610944

Novel biomarkers assist in detection of liver fibrosis in HCV patients

Ejemplares similares